New antibody drug targets Hard-to-Treat kidney disease
NCT ID NCT07234474
First seen Nov 18, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This early-stage trial tests a new drug called YK012 in 66 people with a severe form of primary membranous nephropathy, a kidney disease that hasn't responded to other treatments. The drug is a special antibody designed to target and calm the immune cells causing the kidney damage. The main goal is to check the drug's safety and how the body processes it, while also looking for signs that it might help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.